Dopamine receptor signaling in the forebrain
Recent insights and clinical implications
Citation Manager Formats
Make Comment
See Comments
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Dopamine (DA) is an important modulator of neuronal activity and synaptic plasticity throughout the CNS. The actions of DA are mediated by D1- and D2-type receptors, which are distributed presynaptically, postsynaptically, and extrasynaptically, in projection and interneurons. These receptors utilize phosphorylation cascades or direct membrane interactions to affect the function of voltage- and neurotransmitter-gated channels, cytosolic enzymes, and transcription factors. Via these mechanisms, DA receptors have complex effects on neurotransmitter release, neuronal excitability, synaptic integration, synaptic plasticity, and circuit interactions. D1- and D2-type receptors may also form complexes with each other and with other receptors, which adds to the complexity and flexibility of dopaminergic signaling. In the CNS, DA receptors are primarily distributed in the striatum and frontal cortex, where they affect action selection, exertion of effort, attention and working memory, behavioral activation, and learning from both rewarding and aversive events. Abnormal DA signaling in these circuits is associated with Parkinson disease (PD), dystonia, schizophrenia, drug addiction, and attention-deficit disorders. The manifestations of these conditions reflect both the direct effects of impaired DA receptor signaling and DA receptor-triggered plastic changes in striatal and cortical synapses. The physiology, signaling, and pharmacology of DA receptors and their involvement in disease have been the subject of several reviews.1–8
Footnotes
Go to Neurology.org for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.
- © 2014 American Academy of Neurology
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
More Online
Dr. Deborah Friedman and Dr. Stacy Smith
► Watch
Alert Me
Recommended articles
-
Clinical Implications of Neuroscience Research
Intrinsic circuits of the striatumComplexity and clinical correlationsEduardo E. Benarroch et al.Neurology, March 23, 2016 -
Clinical Implications of Neuroscience Research
Heterogeneity of the midbrain dopamine systemImplications for Parkinson diseaseAnhar Hassan, Eduardo E. Benarroch et al.Neurology, October 16, 2015 -
Articles
In vivo studies on striatal dopamine D1 and D2 site binding in L-dopa-treated Parkinson's disease patients with and without dyskinesiasN. Turjanski, A. J. Lees, D. J. Brooks et al.Neurology, September 01, 1997 -
Clinical Implications of Neuroscience Research
Effects of acetylcholine in the striatumRecent insights and therapeutic implicationsEduardo E. Benarroch et al.Neurology, July 16, 2012